See What HealthDay Can Do For You
Contact Us

Diabetes Glucose, Glycemia Indexes Correlate Well

A1c level more strongly correlated with preprandial than postprandial glucose level

FRIDAY, July 16 (HealthDay News) -- The various indexes used to assess glucose variability and postprandial glycemia generally are well correlated, according to a study in the July issue of Diabetes.

Rikke Borg, M.D., of the Steno Diabetes Center in Copenhagen, Denmark, and colleagues monitored glucose levels for 16 weeks in 507 subjects (268 with type 1 diabetes, 159 with type 2 diabetes, and 80 without diabetes) in the A1c-Derived Average Glucose study. The researchers calculated several indexes of postprandial glycemia, overall hyperglycemia, glucose variability, and A1c, and then analyzed the correlations among the indexes.

The investigators found strong intercorrelation between the indexes of glucose variability. Among postprandial indexes, the area under the glucose curve calculated from continuous glucose monitoring two hours after a meal correlated well with 90-minute self-monitoring of blood glucose (SMBG) postprandial measurements. Fasting blood glucose (FBG) levels exhibited a moderate correlation with hyperglycemia indexes and average or postprandial glucose levels. For SMBG, some time points exhibited a stronger association with A1c than did others. Preprandial glucose levels showed a stronger link to A1c than postprandial values for diabetes -- particularly type 2 diabetes.

"Indexes of glucose variability and average and postprandial glycemia intercorrelate strongly within each category. Variability indexes are weakly correlated with the other categories, indicating that these measures convey different information. FBG is not a clear indicator of general glycemia. Preprandial glucose values have a larger impact on A1c levels than postprandial values," the authors write.

Financial support for the study was provided by a number of pharmaceutical and medical device companies, and Medtronic Minimed, Lifescan, and Hemocue provided supplies and equipment. One co-author disclosed financial ties to Eli Lilly, and another to Novo Nordisk.

Full Text (subscription or payment may be required)

Physician's Briefing